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Accumulating evidence suggests that inflammatorymediators secreted by activated resident or infiltrated innate immune cells have
a significant impact on the pathogenesis of neurodegenerative diseases.Thismay imply that patients affected by a neurodegenerative
disease may benefit from treatment with selective inhibitors of innate immune activity. Here we review the therapeutic potential of
apocynin, an essentially nontoxic phenolic compound isolated from the medicinal plant Jatropha multifida. Apocynin is a selective
inhibitor of the phagocyte NADPH oxidase Nox2 that can be applied orally and is remarkably effective at low dose.
1. Introduction
Ageing societies are facing an increasing prevalence of neu-
rodegenerative diseases. Some relatively prevalent examples
are Alzheimer’s and Parkinson’s disease and less prevalent
are Huntington’s and Lou Gehrig’s disease (amyotrophic
lateral sclerosis; ALS). All neurodegenerative diseases have
in common that no effective treatment exists that can stop
the progressive deterioration of neurological functions. Of
note, none of the neuroprotective agents that have been tested
in the clinic have an efficacy that goes beyond symptoms
control.
In recent years the insight has been growing that inflam-
matory reactions from resident or infiltrated innate immune
cells may have a significant impact on the pathogenesis of
neurodegenerative disorders [1]. A recognized central player
is the microglia, a glial cell that belongs to the myeloid
lineage and is often indicated as the macrophage of the
CNS. This intriguing new insight may imply that drugs
with proven efficacy in the protection of peripheral organs
against the cytotoxic function of innate immune cells, such
as mononuclear or polymorphonuclear phagocytes (resp.,
MNCs and PMNs), might also be useful for the treatment
of the neuroinflammatory component of neurodegenerative
diseases. A major hurdle that drugs need to take is to cross
the blood brain barrier and penetrate the CNS parenchyma
where the neurodegenerative process takes place. In this
review we will discuss preclinical studies highlighting the
potential of apocynin, a small phenolic antioxidant, as treat-
ment of neurodegenerative diseases.
2. Apocynin, a Pharmacologically Active
Plant Phenol
Apocyin (4󸀠-hydroxy-3󸀠-methoxyacetophenone or aceto-
vanillone) was identified as the biologically active substance
in the roots of Picrorhiza kurroa Royle ex Benth, a perennial
plant growing in the alpineHimalaya. Extracts from the roots
are used in the Ayurvedic medical tradition of India and
Sri Lanka for the preparation of ethnic medicines for the
treatment of ailments of liver, heart, joints, and lungs. We
have prepared a 95% ethanolic root extract under controlled
conditions in the laboratory and subjected the prepara-
tion to an activity-guided purification using the oxidative
burst of human polymorphonuclear/neutrophilic granulo-
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Figure 1: Reactive oxygen species produced in the phagocyte
oxidative burst. MPO: myeloperoxidase; NOS: nitric oxide (NO)
synthase.
The read-out assay we used was based on the generation
of luminol-enhanced chemiluminescence by human PMN
stimulated with zymosan opsonized in human serum. The
essence of the assay is that the serum-opsonized yeast
particles stimulate the PMN via surface-exposed receptors
of immunoglobulins or complement factors. The activation
signals relayed via these receptors lead to the emptying of
cytoplasmic granules (degranulation) and the assembly of the
phagocyteNADPHoxidaseNox2.TheNox2 enzyme complex
is assembled frommembrane-bound (gp91phox, p22phox) and
cytoplasmic (p40phox, p47phox, p67phox, and Rac2) subunits
[3]. The assembly process involves phosphorylation of sub-
units by specific kinases and formation of thiol-bridges.
The assembled complex takes up electrons from NADPH
and transfers these onto free molecular oxygen leading to
formation of superoxide anion (O
2
−; one electron reduction)




; two electron reduction). Both
oxidants have cytotoxic activity as could be shown using
red blood cells from different species [4]. The oxidative
burst of PMN comprises a cascade of strongly reactive
oxygen species, collectively indicated as ROS (Figure 1). By
reaction of O
2
− with nitric oxide the strongly cytotoxic





converted into highly reactive hydroxyl radicals (OH∙), which
via peroxidation of membrane lipids affect the fluidity of
cell membranes. Myeloperoxidase released by degranulation











) forming highly toxic hypohalides
(OCl−, OBr−, and OJ−). ROS are essential components of
the intracellular killing of phagocytosed microbes, but when
released into the extracellular milieu they are important


































Figure 2: Inhibition of microglia Nox2 by metabolically activated
apocynin. Receptor-mediated activation of microglia cells induces
production of reactive oxygen species and release of myeloperoxi-




leads to production of a reactive intermediate that stabilizes by
binding to free thiol groups, for example, GSH, or by dimerization.
Dimeric apocynin (diapocynin) inhibits Nox2 activity.
It can be envisaged that components of chemically com-
plex plant extracts can interfere with the read-out assay at
multiple levels and may also exert nonspecific effects such
as killing of the PMN or scavenging of the oxyradicals.
This implies that successful activity-guided purificationneeds
to be well focused and carefully controlled for nonspecific
effects to avoid false positive results. Notwithstanding these
hurdles, we were able to demonstrate a highly specific activity
of apocynin in the assay. Apocynin was found to be metabol-




[7] forming a symmetrical dimer, diapocynin [8] (Figure 2).
The observation that the reaction intermediate could be
trapped with GSH led us to hypothesize that metabolically
activated apocyninmight block the formation of thiol bridges
between the membrane-bound and cytosolic components
that assemble functional Nox2. It was later found, however,
that diapocynin directly inhibits Nox2 superoxide produc-
tion and that this activity is independent of MPO [8]. An
important finding with apocynin has been that it inhibits the
oxidative burst of PMNs, without impeding the intracellular
killing of bacteria. This implies that treatment with apocynin
may prevent collateral damage to tissues infiltrated by acti-
vated PMN without impeding their bactericidal function.
3. Efficacy of Apocynin in AIMID
Animal Models
The initial target disease in which we tested the clinical effect
of apocynin was the WAG/Rij (RT-1u) rat model of collagen-
induced arthritis (CIA), which is an accepted preclinical
model of the autoimmune inflammatory disease (AIMID)
rheumatoid arthritis (RA). In this model, PMNs have a clear
pathogenic role [9], reflecting the situation in RA patients
[6]. In the rat study we chose to administer apocynin at
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a dose range of 0,3 to 200 𝜇g/mL drinking water, which
was provided ad libitum. It was observed that already at
the lowest dose of 0,3 𝜇g/mL, corresponding to a daily oral
dose of 6 𝜇g, the arthritis was almost completely suppressed
[10]. No effect of apocynin on serum levels of anti-collagen
autoantibody or of IL-6, an important pathogenic cytokine
in CIA and RA, was observed, suggesting high selectivity
for the inflammatory component of the disease. Independent
from us, Hougee et al. demonstrated in a mouse CIA
model that orally administered apocynin restores the blocked
production of cartilage proteoglycan in the arthritic joint
[11]. An intriguing side effect of the treatment, illustrating
the powerful anti-inflammatory effect of apocynin, was the
dramatic suppression of the necrotizing skin lesions at the
sites where the immunizing antigen/CFA formulation was
injected [12].
Since its initial identification as potent anti-inflammatory
agent in 1990, apocynin has become an established inhibitor
of the oxidative burst in neutrophils as demonstrated in a
wide range of in vivo models for immune-mediated inflam-
matory disorders affecting peripheral and central organs.
Of particular importance for this review are the promising
clinical effects observed in models of neurodegenerative
disease, including ALS, Alzheimer, and Parkinson’s disease.
In these models the antioxidant activity of apocynin is not
targeted to the neutrophil but to the “macrophage of the
brain,” that is, microglia.
4. Microglia
The brain contains various cell types with the capacity to
exert immune functions including astrocytes, microglia cells,
and macrophages located in the meninges and perivascular
spaces of brain arteries and capillaries [13]. For their immune
tasks these cells are equipped with conserved receptors for
pathogen-associated or damage-associated molecular pat-
terns, which relay activation signals to the cells for inducing
inflammatory effector mechanisms [14].
Microglia are innate immune cells ubiquitously dis-
tributed within the central nervous system where they are
engaged in tight interactionswith neurons, oligodendrocytes,
and astrocytes. However, only microglia release MPO after
stimulation, being a requisite for the metabolic activation of
apocynin.
Microglia in the healthy CNS have a ramified resting phe-
notype. Opposite to earlier concepts, microglia in the healthy
brain are not resting but are highly dynamic cells that carry
out homeostatic surveillance of the extracellular environment
by the extension and retraction of their protrusions and
phagocytosis of tissue debris, which could otherwise cause
inflammation [15]. Activated microglia are found in diseased
CNS tissue, such as within demyelinated cortical grey matter
lesions in the MS brain, surrounding amyloid plaques in
Alzheimer brain and in the degenerating substantia nigra in
Parkinson’s disease [16, 17]. Although the diverse expression
profiles of microglia appear to reflect a broad, continuous
spectrum of activation states, two activation states at both
ends of the spectrum can be recognized corresponding to
theM1 andM2 state designated formacrophages [18]. “Classi-
cally activated”M1microglia, for example, induced by LPS or
IFN𝛾, have proinflammatory functions which are exerted by
the secretion of proinflammatory cytokines such as TNF-𝛼,
IL-1𝛽, and IL-12 and toxic substances such as reactive oxygen
and nitrogen species. “Alternatively activated” M2 microglia,
such as induced in a milieu containing high IL-4 or IL-13
levels, have anti-inflammatory and tissue regenerative activi-
ties, which are mediated by cytokines such as IL-4, IL-10, or
TGF-𝛽 and repair factors such as insulin-like growth factor,
arginase-1, or chitinase-like-1. Not only the cytokine milieu,
but also the redox state of the microenvironment, which is
directly related to NADPH oxidase activity, determines the
functional differentiation of microglia towards an M1 or M2
phenotype [18].
5. Apocynin as a Potential Treatment of
Neurodegenerative Disease
M1microglia cells are themain resource of Nox2 in the brain.
The expression by M1 microglia of activated Nox2 produc-
ing ROS is an essential component of microglia-mediated
neurotoxicity. The broadly accepted notion that microglia-
derived ROS are important mediators of neurodegenera-
tive brain injury raises the question whether the favorable
pharmacological profile and low toxicity of apocynin can
be used for neuroprotective treatment. Microglia cells not
only express Nox2 but also secrete MPO after activation and
could thus potentially exertmetabolic activation of apocynin.
Several authors have reported on the beneficial effect of
apocynin on (models of) acute neurological disorders, such
as ischemia, intracerebral hemorrhage, and stroke (reviewed
in [19]). What are the perspectives for apocynin in chronic
neurodegenerative disorders?
In vitro studies using cultured microglia have impli-
cated Nox2-derived ROS in the proliferation and functional
polarization of microglia [20, 21]. A crucial finding has
been that inhibition of Nox2 promotes alternative and anti-
inflammatory microglia activation during neuroinflamma-
tion [22]. This implies that suppression of Nox2 with apoc-
ynin might restore a healthy balance between a proinflam-
matory M1 and an anti-inflammatory/proregenerative M2
phenotype of microglia. Others have shown that apocynin
lowers the production of IL-1𝛽, TNF-𝛼, and nitric oxide
by microglia, thus interrupting a self-perpetuating cycle of
detrimental activity. While the exact neurotoxic mechanism
of activated microglia in neurodegenerative disease is still
uncertain, it is also of considerable interest that the release
of the excitotoxin glutamate requires Nox2 activity and that
this can be inhibited by apocynin [23]. Taken together,
these data suggest a potentially beneficial role of apocynin
in neurodegenerative disease. Indeed, promising effects of
apocynin have been observed in mouse models of some
major neurodegenerative diseases.
Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig Disease).
Amyotrophic lateral sclerosis is a common adult-onset neu-
rodegenerative disease affecting motor neurons. The disease
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leads to rapidly progressing motoric impairment and death
usually within 5 years. While in the majority of patients the
cause of the disease is unknown, in a subset of cases the dis-
ease has a genetic cause, namely, mutations in the superoxide
dismutase-1 (SOD1) gene [24, 25]. The mutation enhances
oxidative stress by dysregulated production of superoxide





expressing astrocytes are linked to ALS pathology because
of their reduced capacity to absorb glutamate [26] and/or by
their release of neurotoxic factors [27]. Selective silencing of
mutant SOD1 [28] or replacement of mutant by wild-type
microglia [29] in the mutant SOD1 mouse model strongly
point to a central pathogenic role of microglia. Harraz et al.
have used oral apocynin to control progression of neurode-
generation in a SOD1 mutant mouse model and observed
promising effects [30]; it was observed that administration
of apocynin in the drinking water significantly prolonged
survival and delayed the onset of motoric defects. This study
shows that orally administered apocynin can build up a
sufficiently high concentration within the CNS parenchyma
formitigating neurotoxic levels of ROS production. However,
these promising data could not be reproduced in another
study using the same mutant mouse strain [31].
Alzheimer Disease (AD). Alzheimer disease is an ageing-
associated progressive neurological disorder leading to irre-
versible dementia. Neuropathological hallmarks of AD are
senile plaques ofmisfolded and fibrillar amyloid-𝛽 aggregates
and intraneuronal tangles of tau protein within the cerebral
cortex [32]. Activated microglia cells were found clustered
around senile plaques producing neurotoxic agents like ROS,
NO, and TNF-𝛼. Activation of microglia Nox2 by oligomeric
and/or fibrillar amyloid-𝛽 [33, 34] and expression of activated
Nox2 in Alzheimer brain [35] have been reported.
Lull et al. have tested apocynin at a daily oral dose of
10mg/kg via the drinking water in a hAPP(751)SL transgenic
mouse model of AD [36].They observed in apocynin-treated
mice a significant reduction of plaque size within cortex
and hippocampus and a reduction of microglia numbers
in the cortex, but not in the hippocampus. However, a
behavioral feature of AD observed in this mouse model, that
is, performance in the Morris water maze swim test, which
tests spatial memory organized in the hippocampus, was not
markedly improved by the treatment. The limited clinical
effect of apocynin in the model might be due to the absence
of clear neuroinflammation, while this is more prominent in
AD patients, and because of the fact that plaque formation
does not necessarily predict cognitive decline.
Parkinson’s Disease (PD). The pathological hallmark of PD
is a progressive degeneration of dopamine producing neu-
rons in the substantia nigra (SN), a pigmented structure
located in the bottom of the midbrain. Via the release of
dopamine, the SN has a central role in the coordination of
various neurological functions, including reward, addiction,
and movement. The latter function is particularly disturbed
in PD. To compensate for dopamine loss, a metabolically
stable precursor of dopamine (L-DOPA) is given, which in
a substantial number of patients causes typical involuntary
movements known as hyperkinetic syndrome. While in the
vast majority of (sporadic) PD patients the cause of the
disease is not known, in a small fraction a genetic cause has
been found, namely, mutations in several genes, including
alpha-synuclein, parkin, leucine-rich repeat kinase 2, PTEN-
induced putative kinase 1, andATP13A2 [25].Theobservation
that users of heroin contaminated with MPTP developed PD
symptoms [37] enabled generation of a clinically relevant
animal PD model. After conversion of MPTP into MPP+ by
monoamine oxidase B in astrocytes,MPP+ is concentrated in
dopaminergic cells via uptake through the specific dopamine
transporter, where it blocks complex I of the mitochondrial
respiratory chain. The ensuing redox stress causes amongst
others dysregulation of cellular Ca2+ leading to cell death. Just
like in ALS and AD, neurodegeneration in PD is found to be
associated with microglia Nox2 activation, which is thought
to contribute significantly to the pathogenic process [38].
Using an in vitro system, Gao et al. demonstrated that
ROS generated by microglia Nox2 enhances the sensitivity
of dopaminergic neurons to MPP+ [39]. A beneficial effect
of apocynin on neurotoxic effects mediated by microglia has
been shown in a mouse model of PD [40].
6. The Effect of Apocynin in a Nonhuman
Primate Parkinson’s Disease Model
Repetitive injection of a low dose of MPTP in common
marmosets, a small-bodied neotropical primate, elicits a
neurological disease that at the level of clinical and neu-
ropathological presentation closely approximates PD [41].We
have used this MPTP model in 5 marmoset twins to test
whether oral apocynin is also effective in a higher species [35].
For oral administration, apocynin was dissolved in Arabic
gum; one sibling of each twin was given apocynin containing
gum and the other was given only the gum. Treatment
with apocynin (100mg/kg, TID) started one week before PD
induction with MPTP (1mg/kg, via subcutaneous injection
for 8 days). Apocynin limited the typical body weight loss
associated with the parkinsonian syndrome. Also the motor
function in the apocynin treated monkeys was improved,
indicating an anti-Parkinson efficacy of apocynin. Moreover,
the number of surviving dopamine neurons was increased by
apocynin, indicating a neuroprotective efficacy. Remarkably,
apocynin has a similar molecular structure as homovanillic
acid (HVA), a metabolite of dopamine. An explanation of the
protective efficacy of apocynin in PDmight also be related to
the compensation of the reduced level of the natural available
o-methoxycatechol HVA.
7. Perspective for Treatment of
Human Patients
Apocynin is a potentially attractive oral prodrug because of its
low general toxicity and the fact that its specific antioxidant
action is elicited after metabolic activation by MPO releasing
phagocytic cells. Safety data of apocynin are scarce, but
those available show low toxicity and high stability (partly
reviewed in [19]).The LD50 after oral dosing inmice has been
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estimated at 9 g/kg. In rats about 80% of intraperitoneally
injected apocynin at 120mg/kg was recovered in unchanged
form in a urine sample collected 20 hours later. An intra-
venous dose of 420mg/kg apocynin in mice caused minimal
signs of toxicity [12].
To our knowledge, apocynin has not been tested in
human neurodegenerative disease patients. However, Peters
et al. have evaluated the therapeutic potential of inhaled
apocynin on ozone-induced bronchial hyperresponsiveness
to methacholine in asthmatic patients as a model of inflam-
matory lung disease [42].The authors could exclude scaveng-
ing of ozone by apocynin and concluded that the effect was
mitigating ROS production by PMNs and eosinophils that
had infiltrated the lung upon ozone exposure.
The mouse studies discussed in this review show that
low doses of apocynin administered via the oral route reach
the CNS parenchyma in a sufficient concentration to inhibit
the microglia oxidative burst and inhibit neurodegeneration.
Taking the very low systemic toxicity and the highly specific
mode of action of apocynin into account it would be an
attractive perspective to test the therapeutic value in human
neurodegenerative disease.
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